β-Cell Function and Diabetes Outcomes 1 Year After Stopping Oral Baricitinib Immunotherapy for Type 1 Diabetes
Year: 2026
Type: article
Source: Diabetes Care
DOI: 10.2337/dc26-1072
Authors: Michelle So, Michaela Waibel, Jennifer J. Couper, Fergus J. Cameron, Richard J. MacIsaac, Gabby Atlas, Alexandra Gorelik, Sara Vogrin, Sara Litwak, Laura Sanz-Villanueva, Prerak Trivedi, Jessica E. Harbison, Candice Hall, Balasubramanian Krishnamurthy, Peter G. Colman, Leonard C. Harrison, Helen E. Thomas, Thomas W.H. Kay, John M. Wentworth, Baricitinib in New-Onset Type 1 Diabetes (BANDIT) Study Group:, Thomas Kay, Helen Thomas, Michelle So, Bala Krishnamurthy, Michaela Waibel, Madeleine Doyle, Stuart Mannering, Sara Litwak, Laura Sanz-Villanueva, Tara Catterall, Prerak Trivedi, Tom Brodnicki, Katherine Woods, Lisa Kuspira, Nicole Kruger, Alexandra Gorelik, John Wentworth, Candice Hall, Vicky Gonzalez, Renee Kludas, Felicity Healy, Leanne Redl, Len Harrison, Peter Colman, Richard MacIsaac, Madeleine Masterton, Elizabeth Mulrooney, Jane Keenan, Fergus Cameron, Gabby Atlas, Rebecca Gebert, Wing Fai Nip, Sarah Lee, Jennifer Couper, Jessica Harbison, Kirsty Herewane, Dao Hoa Anh Huynh, Madeleine Hall, Mandy Anderson, Maria Craig, Joe Sasadeusz, Stephan Mynhardt, Anouk Koopman-Daemen, Kate Murphy, Moses Mwangi
Institutions: The Royal Melbourne Hospital, St Vincents Institute of Medical Research, Women's and Children's Hospital, Adelaide University, The University of Adelaide, Royal Children's Hospital, The University of Melbourne, Murdoch Children's Research Institute, St Vincent's Hospital Melbourne, Monash University, UNSW Sydney, Walter and Eliza Hall Institute of Medical Research
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7203875221
FWCI:
Cites:
Cited by:
Related to: